Involvement of macrophage migration inhibitory factor and its receptor (CD74) in human breast cancer

Richard,Vincent; Kindt,Nadège; Decaestecker,Christine; Gabius,Hans‑Joachim; Laurent,Guy; Noël,Jean-Christophe; Saussez,Sven

doi:10.3892/or.2014.3272

Involvement of macrophage migration inhibitory factor and its receptor (CD74) in human breast cancer

Authors:
- Vincent Richard
- Nadège Kindt
- Christine Decaestecker
- Hans‑Joachim Gabius
- Guy Laurent
- Jean-Christophe Noël
- Sven Saussez
View Affiliations

Affiliations: Laboratory of Anatomy and Cellular Biology, Faculty of Medicine and Pharmacy, University of Mons, B-7000 Mons, Belgium, Laboratory of Image, Signal Processing and Acoustics, Ecole Polytechnique de Bruxelles, B-1050 Brussels, Belgium, Institute of Physiological Chemistry, Faculty of Veterinary Medicine, Ludwig Maximilians University, D-80539 Munich, Germany, Laboratory of Histology, Faculty of Medicine and Pharmacy, University of Mons, B-7000 Mons, Belgium, Department of Pathology, Erasme Hospital, B-1070 Brussels, Belgium
Published online on: June 16, 2014 https://doi.org/10.3892/or.2014.3272
Pages: 523-529
Copyright: © Richard et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Macrophage migration inhibitory factor (MIF) and its receptor CD74 appear to be involved in tumorigenesis. We evaluated, by immunohistochemical staining, the tissue expression and distribution of MIF and CD74 in serial sections of human invasive breast cancer tumor specimens. The serum MIF level was also determined in breast cancer patients. We showed a significant increase in serum MIF average levels in breast cancer patients compared to healthy individuals. MIF tissue expression, quantified by a modified Allred score, was strongly increased in carcinoma compared to tumor-free specimens, in the cancer cells and in the peritumoral stroma, with fibroblasts the most intensely stained. We did not find any significant correlation with histoprognostic factors, except for a significant inverse correlation between tumor size and MIF stromal positivity. CD74 staining was heterogeneous and significantly decreased in cancer cells but increased in the surrounding stroma, namely in lymphocytes, macrophages and vessel endothelium. There was no significant variation according to classical histoprognostic factors, except that CD74 stromal expression was significantly correlated with triple-negative receptor (TRN) status and the absence of estrogen receptors. In conclusion, our data support the concept of a functional role of MIF in human breast cancer. In addition to auto- and paracrine effects on cancer cells, MIF could contribute to shape the tumor microenvironment leading to immunomodulation and angiogenesis. Interfering with MIF effects in breast tumors in a therapeutic perspective remains an attractive but complex challenge. Level of co-expression of MIF and CD74 could be a surrogate marker for efficacy of anti-angiogenic drugs, particularly in TRN breast cancer tumor.

View Figures

View References

1	Altekuse SF, Kosary CL, Krapcho M, et al: SEER Cancer Statistics Review, 1975–2007. NCI; Bethesda: 2010
2	Grieb G, Merk M, Bernhagen J and Bucala R: Macrophage migration inhibitory factor (MIF): a promising biomarker. Drug News Perspect. 23:257–264. 2010. View Article : Google Scholar : PubMed/NCBI
3	Santos LL and Morand EF: Macrophage migration inhibitory factor: a key cytokine in RA, SLE and atherosclerosis. Clin Chim Acta. 399:1–7. 2009. View Article : Google Scholar : PubMed/NCBI
4	Conroy H, Mawhinney L and Donnelly SC: Inflammation and cancer: macrophage migration inhibitory factor (MIF) - the potential missing link. QJM. 103:831–836. 2010. View Article : Google Scholar : PubMed/NCBI
5	Mitchell RA: Mechanisms and effectors of MIF-dependent promotion of tumourigenesis. Cell Signal. 16:13–19. 2004. View Article : Google Scholar : PubMed/NCBI
6	Rendon BE, Willer SS, Zundel W and Mitchell RA: Mechanisms of macrophage migration inhibitory factor (MIF)-dependent tumor microenvironmental adaptation. Exp Mol Pathol. 3:180–185. 2009. View Article : Google Scholar : PubMed/NCBI
7	Tarnowski M, Grymula K, Liu R, et al: Macrophage migration inhibitory factor is secreted by rhabdomyosarcoma cells, modulates tumor metastasis by binding to CXCR4 and CXCR7 receptors and inhibits recruitment of cancer-associated fibroblasts. Mol Cancer Res. 8:1328–1343. 2010. View Article : Google Scholar
8	Martinez LM, Vallone VB F, Labovsky V, et al: Changes in the peripheral blood and bone marrow from untreated advanced breast cancer patients that are associated with the establishment of bone metastases. Clin Exp Metastasis. 31:213–232. 2014. View Article : Google Scholar : PubMed/NCBI
9	Lue H, Thiele M, Franz J, et al: Macrophage migration inhibitory factor (MIF) promotes cell survival by activation of the AKT pathway and role for CSN5/JAB1 in the control of autocrine MIF activity. Oncogene. 26:5046–5059. 2007. View Article : Google Scholar : PubMed/NCBI
10	Bernhagen J, Krohn R, Lue H, et al: MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat Med. 13:587–596. 2007. View Article : Google Scholar : PubMed/NCBI
11	Zernecke A, Bernhagen J and Weber C: Macrophage migration inhibitory factor in cardiovascular disease. Circulation. 117:1594–1602. 2008. View Article : Google Scholar : PubMed/NCBI
12	Mitchell RA, Liao H, Chesney J, Fingerle-Rowson G, Baugh J, David J and Bucala R: Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: regulatory role in the innate immune response. Proc Natl Acad Sci USA. 99:345–350. 2002. View Article : Google Scholar : PubMed/NCBI
13	Fersching DMI, Nagel D, Siegele B, Salat C, Heinemann V, Holdenrieder S and Stoetzer OJ: Apoptosis-related biomarkers sFAS, MIF, ICAM-1 and PAI-1 in serum of breast cancer patients undergoing neoadjuvant chemotherapy. Anticancer Res. 32:2047–2058. 2012.PubMed/NCBI
14	Verjans E, Noetzel E, Bektas N, et al: Dual role of macrophage migration inhibitory factor (MIF) in human breast cancer. BMC Cancer. 9:2302009. View Article : Google Scholar : PubMed/NCBI
15	Bando H, Matsumoto G, Bando M, et al: Expression of macrophage migration inhibitory factor in human breast cancer: association with nodal spread. Jnp J Cancer Res. 93:389–396. 2002.PubMed/NCBI
16	Xu X, Wang B, Ye C, et al: Overexpression of macrophage migration inhibitory factor induces angiogenesis in human breast cancer. Cancer Lett. 261:147–157. 2008. View Article : Google Scholar : PubMed/NCBI
17	Tian B, Zhang Y, Li N, Liu X and Dong J: CD74: a potential novel target for triple-negative breast cancer. Tumour Biol. 33:2273–2277. 2012. View Article : Google Scholar : PubMed/NCBI
18	Greenwood C, Metodieva G, Al-Janabi K, et al: Stat1 and CD74 overexpression is co-dependent and linked to increased invasion and lymph node metastasis in triple-negative breast cancer. J Proteomics. 75:3031–3040. 2012. View Article : Google Scholar : PubMed/NCBI
19	Metodieva G, Correa Nogueira-de-Souza N, Greenwood C, Al-Janabi K, Leng L, Bucala R and Metodiev MV: CD74-dependent deregulation of the tumor suppressor scribble in human epithelial and breast cancer cells. Neoplasia. 15:660–668. 2013.PubMed/NCBI
20	Schulz R, Marchenko ND, Holemboswki, et al: Inhibiting the HSP90 chaperone destabilizes macrophage migration inhibitory factor and thereby inhibits breast tumor progression. J Exp Med. 209:275–289. 2012. View Article : Google Scholar
21	Govindan SV, Cardillo TM, Sharkey RM, Tat F, Gold DV and Goldenberg DM: Milatuzumab-SN-38 conjugates for the treatment of CD74⁺cancers. Mol Cancer Ther. 12:968–978. 2013. View Article : Google Scholar : PubMed/NCBI
22	Hammond EH, Hayes DF, Dowsett M, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med. 134:48–72. 2010.
23	Dowset M, Nielsen TO, A’Hern R, et al: Assesment of Ki67 in breast cancer: recommendations from the international Ki67 in breast cancer working group. J Natl Cancer Inst. 103:1656–1664. 2011. View Article : Google Scholar : PubMed/NCBI
24	Schrohl AS, Pedersen HC, Jensen SS, Nielsen S and Brünner N: Human epidermal growth factor receptor (HER2) immunoreactivity: specificity of three pharmacodiagnostic antibodies. Histopathology. 59:975–983. 2011. View Article : Google Scholar
25	Preat F, Simon P and Noel JC: Differences in breast carcinoma immunohistochemical subtypes between immigrant Arab and European women. Diagn Pathol. 9:262014. View Article : Google Scholar : PubMed/NCBI
26	Cludts S, Decaestecker Ch, Johnson B, et al: Increased expression of macrophage migration inhibitory factor during progression to hypopharyngeal squamous cell carcinoma. Anticancer Res. 30:3313–3319. 2010.PubMed/NCBI
27	Kindt N, Lechien J, Decaestecker C, et al: Expression of macrophage migration-inhibitory factor is correlated with progression in oral cavity carcinomas. Anticancer Res. 32:4499–4505. 2012.PubMed/NCBI
28	Jesneck JL, Mukherjee S, Yurkovetsky Z, Clyde M, Marks JR, Lorkshin AE and Lo JY: Do serum biomarkers really measure breast cancer? BMC Cancer. 9:1642009. View Article : Google Scholar : PubMed/NCBI
29	Simpson KD, Templeton DJ and Cross JV: Macrophage migration inhibitory factor promotes tumor growth and metastasis by inducing myeloid-derived suppressor cells in the tumor microenvironment. J Immunol. 189:5533–5540. 2012. View Article : Google Scholar
30	Kim H, Lee S, Kim JH, et al: Elevated levels of macrophage migration inhibitory factor in women with metabolic syndrome. Horm Metab Res. 43:642–645. 2011. View Article : Google Scholar : PubMed/NCBI
31	Kolar M, Szabo P, Dvorankova B, et al: Upregulation of IL-6, IL-8 and CXCL-1 production in dermal fibroblasts by normal/malignant epithelial cells in vitro: Immunohistochemical and transcriptomic analyses. Bio Cell. 104:738–751. 2012. View Article : Google Scholar
32	Catteau X, Simon P, Vanhaeverbeek M and Noël JC: Variable stromal periductal expression of CD34 and smooth muscle actin (SMA) in intraductal carcinoma of the breast. PLoS One. 8:e57732013. View Article : Google Scholar : PubMed/NCBI
33	Meyer-Siegler KL, Iczkowski KA and Vera PL: Further evidence for increased macrophage migration inhibitory factor expression in prostate cancer. BMC Cancer. 5:732005. View Article : Google Scholar : PubMed/NCBI
34	McClelland M, Zhao L, Carskadon S and Arenberg D: Expression of CD74, the receptor for macrophage migration inhibitory factor, in non-small cell lung cancer. Am J Pathol. 174:638–646. 2009. View Article : Google Scholar : PubMed/NCBI
35	von Minckwitz G, Eidtmann H, Rezai M, et al: Neoadjuvant chemotherapy and bevacizumab for HER-2 negative breast cancer. N Engl J Med. 366:299–309. 2012.PubMed/NCBI
36	Simpsons KD and Cross JV: MIF metastasis/MDSC-inducing factor? Oncoimmunology. 2:32013.PubMed/NCBI
37	Zhang L, Ye SB, Ma G, et al: The expressions of MIF and CXCR4 protein in tumor microenvironment are adverse prognostic factors in patients with esophageal squamous cell carcinoma. J Transl Med. 11:602013. View Article : Google Scholar : PubMed/NCBI
38	Du W, Wright BM, Li X, et al: Tumor-derived macrophage migration inhibitory factor promotes an autocrine loop that enhances renal cell carcinoma. Oncogene. 32:1469–1474. 2013. View Article : Google Scholar : PubMed/NCBI